Alnylam v. Pfizer: LNP Patent Noninfringement Ruling Explained
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Alnylam Pharmaceuticals, Inc. v. Pfizer, Inc. et al. |
| Case Number | 1:22-cv-00336 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Mar 2022 – Jul 2025 3 years 4 months |
| Outcome | Defendant Win – Noninfringement |
| Patents at Issue | |
| Accused Products | Pfizer’s COMIRNATY® COVID-19 vaccine |
Case Overview
The Parties
⚖️ Plaintiff
Cambridge, Massachusetts-based biopharmaceutical company widely credited with commercializing RNA interference (RNAi) therapeutics and LNP drug delivery technology. Pioneer of ONPATTRO®.
🛡️ Defendant
One of the world’s largest pharmaceutical companies, co-developer of COMIRNATY® COVID-19 vaccine, utilizing LNP delivery technology.
Patents at Issue
This landmark case involved U.S. Patent No. 11,246,933, covering LNP technology critical to nucleic acid delivery, with claims encompassing specific lipid compositions including cationic lipid components.
- • US 11,246,933 — LNP formulation technology with claims encompassing specific cationic lipid components.
Developing an RNA therapeutic product?
Check if your LNP formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The court entered **final judgment of noninfringement** of all asserted claims of U.S. Patent No. 11,246,933, resolving the dispute in favor of Pfizer. No damages were awarded to Alnylam.
Claim Construction: The “Cationic Lipid” Pivot
The dispositive legal issue was the construction and application of the **”cationic lipid” claim limitations** in U.S. Patent No. 11,246,933. Pfizer’s Summary Judgment Motion No. 4 argued that COMIRNATY®’s LNP formulation did not satisfy these limitations as properly construed—a position Alnylam ultimately did not contest.
The turning point came when Judge Connolly **denied Alnylam’s O2 Micro motion** on April 28, 2025. This effectively foreclosed Alnylam’s preferred claim construction path, critically undermining its infringement theory.
Expert Testimony and the Daubert Dimension
The court’s April 2025 order also addressed Alnylam’s **partial Daubert motion** challenging the opinions of Dr. Steven R. Little, Pfizer’s expert witness on LNP chemistry. The denial of this motion—combined with the claim construction adverse ruling—left Alnylam without a viable evidentiary path to prove infringement.
Drafting LNP patents?
Learn from this case. Use AI to draft stronger claims explicitly addressing ionizable lipids.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in LNP drug delivery. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation, particularly the cationic vs. ionizable lipid distinction.
- View all related LNP patents in this technology space
- See which companies are most active in RNA therapeutics IP
- Understand claim construction patterns for LNP compositions
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own LNP technology or RNA therapeutic product.
- Input your LNP composition or therapeutic description
- AI identifies potentially blocking patents (cationic/ionizable)
- Get actionable risk assessment report
Critical Claim Distinction
Cationic vs. Ionizable Lipids
Extensive LNP Portfolio
RNA Therapeutics Landscape
Strategic FTO Planning
Early Claim Analysis is Key
✅ Key Takeaways
For Patent Attorneys & Litigators
Claim construction of “cationic lipid” vs. “ionizable lipid” is now a precedent-relevant issue in LNP patent litigation.
Search related case law →Denial of an O2 Micro motion can be strategically fatal to an infringement case; manage claim construction early.
Explore precedents →Prosecution strategy for LNP patents must explicitly address ionizable lipid architectures to capture modern mRNA vaccine delivery systems.
Try AI patent drafting →For R&D Teams
Ionizable lipid formulations may offer design-around freedom relative to “cationic lipid” patent claims—verify with current FTO counsel.
Start FTO analysis for my product →Document the scientific basis for lipid classification decisions thoroughly during product development.
Request expert IP consultation →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.